- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/04 - Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Patent holdings for IPC class A61P 7/04
Total number of patents in this class: 1602
10-year publication summary
|
69
|
49
|
59
|
99
|
126
|
117
|
159
|
140
|
161
|
37
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 220 |
53 |
| Takeda Pharmaceutical Company Limited | 2961 |
42 |
| Chugai Seiyaku Kabushiki Kaisha | 1259 |
29 |
| The Children's Hospital of Philadelphia | 716 |
24 |
| Cellphire, Inc. | 108 |
21 |
| CSL Behring Lengnau AG | 130 |
20 |
| Genzyme Corporation | 1205 |
17 |
| Laboratoire Francais du Fractionnement et des Biotechnologies | 306 |
17 |
| Novo Nordisk Health Care AG | 342 |
17 |
| Novo Nordisk A/S | 2324 |
17 |
| Baxter International Inc. | 2425 |
15 |
| Pfizer Inc. | 3322 |
14 |
| Baxter Healthcare S.A. | 1810 |
14 |
| Baxalta Incorporated | 306 |
12 |
| CSL Behring GmbH | 350 |
11 |
| The University of North Carolina at Chapel Hill | 1928 |
11 |
| Bayer HealthCare LLC | 1415 |
10 |
| The General Hospital Corporation | 4517 |
10 |
| Cantab Biopharmaceuticals Patents Limited | 19 |
10 |
| CSL Limited | 251 |
10 |
| Other owners | 1228 |